C4A-27424-70449
3 vaccinations
2 coded responses
40 check-ins
2 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 16-20
- ZIP prefix
- 450 / OH
- Registered
- 2021-04-02
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-02
Registered in v-safe
-
2021-04-02
Dose 1 — Pfizer-BioNTech
- 2021-04-02
-
2021-04-03
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Muscle or body achesAdult check-in
- 2021-04-04
- 2021-04-05
- 2021-04-06
- 2021-04-07
- 2021-04-08
- 2021-04-09
- 2021-04-16
-
2021-04-23
Dose 2 — Pfizer-BioNTech
- 2021-04-23
-
2021-04-24
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain · Fever · Chills, Muscle or body aches, Fatigue or tiredness, Nausea, Diarrhea · Be unable to do your normal daily activitiesAdult check-in
-
2021-04-25
Health check-in — days 1–6 daily, dose 2Feeling: Good · Headache, Fatigue or tiredness, NauseaAdult check-in
- 2021-04-26
- 2021-04-27
- 2021-04-28
- 2021-04-29
- 2021-04-30
- 2021-05-07
- 2021-05-14
- 2021-05-21
- 2021-05-28
- 2021-06-04
- 2021-07-24
- 2021-10-22
-
2021-12-17
Dose 3 — Pfizer-BioNTech
-
2021-12-17
Health check-in — day 0, dose 3Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tirednessAdult check-in
-
2021-12-18
Health check-in — days 1–6 daily, dose 3Feeling: Poor · Site: Pain, Swelling · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea, Diarrhea · Be unable to do your normal daily activitiesAdult check-in
- 2021-12-19
- 2021-12-20
- 2021-12-21
- 2021-12-22
- 2021-12-23
- 2021-12-24
- 2021-12-31
- 2022-01-07
- 2022-01-14
- 2022-01-21
- 2022-01-28
- 2022-03-20
-
2022-06-17
Survey response — 6 months, dose 3MedDRA: COVID-19, Catarrh, Dyspnoea, Pyrexia — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: I got Covid-19 and experienced moderate to moderate-severe symptoms. My symptoms largely lasted for 5 days, peaking during the 3rd day with a fever of 103.5 Fahrenheit. I experienced difficulty breathing due to mucus build up in my lungs.MedDRA releases: 2024-11 · check-in free text available
-
2022-12-17
Survey response — 12 months, dose 3MedDRA: Blindness transient — Feeling: Good · Be unable to do your normal daily activitiesFree text: I had an unexplained instance of whited out vision that lasted around 30 seconds on 11/30/22. NOT accompanied by dizziness or feelings of passing outI was fully conscious. It took place during my normal workday while sitting (and having had been).MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-02 | Pfizer-BioNTech | |
| 2 | 2021-04-23 | Pfizer-BioNTech | |
| 3 | 2021-12-17 | Pfizer-BioNTech | No |
Free text
Release 12 — 6 months, dose 3
Symptoms: I got Covid-19 and experienced moderate to moderate-severe symptoms. My symptoms largely lasted for 5 days, peaking during the 3rd day with a fever of 103.5 Fahrenheit. I experienced difficulty breathing due to mucus build up in my lungs.
Release 12 — 12 months, dose 3
Symptoms: I had an unexplained instance of whited out vision that lasted around 30 seconds on 11/30/22. NOT accompanied by dizziness or feelings of passing outI was fully conscious. It took place during my normal workday while sitting (and having had been).
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Blindness transient | · | · | ✓ |
| SD | Catarrh | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release